ORLANDO, FL / ACCESS Newswire / September 10, 2025 / Exousia Pro, Inc. (OTCPINK:MAJI), a clinical-stage biotechnology company and innovator in exosome-based therapies, today announced a key strategic ...

ORLANDO, FL / ACCESS Newswire / December 11, 2025 / Exousia Pro, Inc. (OTCID:MAJI), a clinical-stage biotechnology company focused on proprietary exosome-based delivery systems, is excited to announce ...

Exousia Health is expected to have an initial patient base of 1,000 active clients, projected to generate approximately $50,000 in monthly revenue. Following the acquisition closing, Exousia Health is ...

ORLANDO, FLORIDA / ACCESS Newswire / November 17, 2025 / Exousia Pro, Inc. (OTCID:MAJI), a clinical-stage biotechnology company focused on advanced exosome-based delivery systems, today announced it ...

Exousia Pro is in a unique position, as only 11% of ODAs are awarded at the preclinical stage. ORLANDO, FLORIDA / ACCESS Newswire / October 28, 2025 / Exousia Pro, Inc. (formerly Marijuana, Inc.) ...

Dr. Marvin Hausman is joining Exousia Pro as a Consultant and will host a weekly series. Exousia Pro is a clinical-stage biotechnology company developing new ways to exploit the therapeutic potential ...

Exousia Pro is a clinical-stage biotechnology company developing new ways to exploit the therapeutic potential of exosomes, initially focused on oncology. The company's patented manufacturing process ...

ORLANDO, FL / ACCESS Newswire / April 29, 2025 / MARIJUANA INC. (OTCPINK:MAJI), dba Exousia Pro, Inc., a clinical-stage biotech company utilizing exosomes in therapies helpful in the treatment of ...

Exousia Pro's exome-based treatment for GBM has received FDA orphan drug designation, offering incentives like tax benefits and market exclusivity. The company's exosomal technology delivers genetic ...

Exousia Health is expected to have an initial patient base of 1,000 active clients, projected to generate approximately $50,000 in monthly revenue. ORLANDO, FL / ACCESS Newswire / September 8, 2025 / ...